All In MedTech

Device Trial Radar · NCT07316192

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

Outcomes With Pelashield™ PainGuard™ Compared to Restrata® in Standard Two-Stage Excision and Closure for Hidradenitis Suppurativa: A Prospective Cohort With Retrospective Comparator

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Sep 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Rutgers, The State University of New JerseyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 5, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hidradenitis Suppurativa (HS) is a long-lasting skin condition that causes painful lumps and infections. In severe cases, patients need surgery to remove the affected skin. After surgery, a wound dressing called a wound matrix is placed over the area to help the skin heal. This study will compare two different wound matrices: Restrata®, which is the current standard treatment. Pelashield™ PainGuard™, a newer dressing that contains silver to reduce bacteria and lidocaine to help with pain. The goal of this research is to find out if Pelashield™ PainGuard™ helps patients heal better after surgery than Restrata®. We will look at: How quickly healthy granulation tissue (new healing tissue) forms How soon the wound is ready for the second surgery to apply a skin graft How often infections happen after surgery How much narcotic (opioid) pain medication patients need after surgery Patients who receive Pelashield™ PainGuard™ will be enrolled in the study going forward (prospective group). Patients who previously had surgery with Restrata® will be included through a review of their medical records (retrospective group). No additional procedures will be done outside of standard surgical care.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

  • Pelashield PainguardDevice

    This is the only intervention being used in this study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Postoperative Opioid Analgesic UsageTime frame: Period 1: After Stage 1 excision through day before Stage 2 closure (up to 8 weeks starting one day after surgery 1) Period 2: Stage 2 closure through 30 days post-Stage 2
  2. ReCell Skin Graft IncorporationTime frame: Assessment performed at 14 days (±3 days) post-Stage 2 during routine clinic follow-up
  3. Surgical Site Infection (SSI) During Wound Bed PreparationTime frame: After Stage 1 excision through day before Stage 2 closure (up to 8 weeks starting one day after surgery 1)

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital

    Newark, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.